Compare HSDT & LONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HSDT | LONA |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | 21 | 19 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.2M | 90.4M |
| IPO Year | N/A | N/A |
| Metric | HSDT | LONA |
|---|---|---|
| Price | $1.48 | $8.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | $4.00 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 287.1K | 35.2K |
| Earning Date | 05-19-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $91.56 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.30 | $4.21 |
| 52 Week High | $25.50 | $14.21 |
| Indicator | HSDT | LONA |
|---|---|---|
| Relative Strength Index (RSI) | 27.64 | 39.51 |
| Support Level | N/A | $8.10 |
| Resistance Level | $2.39 | $9.88 |
| Average True Range (ATR) | 0.16 | 1.00 |
| MACD | -0.09 | -0.19 |
| Stochastic Oscillator | 4.62 | 3.10 |
Solana Co is a publicly listed digital asset treasury established in partnership with Pantera and Summer Capital. The company is dedicated to acquiring Solana (SOL) and aims to maximize SOL per share by strategically leveraging capital market opportunities and on-chain activities. Through this model, Solana Company provides public market investors with efficient and direct exposure to Solana's long-term growth potential.
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.